ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: INTRA-NCI Scramble For Funds involves “Tricks, Machinations, Day To Day Battle”

July 16, 1976

In Brief: FDA approves Three-Hour Taxol Infusion; Foti Elected President Of NCCR; Luce Retires

September 9, 1994

Cancer Centers: John Glick to step down after 21 years directing Penn’s Abramson Cancer Center.

December 2, 2005

In Brief: UICC Publishes International directory Of Cancer Centers; HSAs Still Worry NCI

January 7, 1977

NCI Raises R01 Payline To 16th Percentile FY09. Coalition Formed To Advocate For Medical Innovation

March 27, 2009

Overwhelming 89 To 7 Vote By Senate Overturns President Reagan’s Veto Of NIH Reauthorization

November 29, 1985